Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.72), $0.15 worse than the analyst estimate of ($1.57). Revenue for the quarter came in at $187.6 million versus the consensus estimate of $218.54 million.

2021 Financial Guidance

2021 Financial Guidance

Full year 2021 financial guidance is reiterated and consists of the following:

Combined net product revenues for ONPATTRO, GIVLAARI and OXLUMO		$640 million - $665 million
Net revenues from collaborations and royalties		$150 million - $200 million
GAAP R&D and SG&A expenses		$1,335 million - $1,455 million
Non-GAAP R&D and SG&A expenses*		$1,175 million - $1,275 million

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.